We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | NASDAQ:KNSA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -0.52% | 19.17 | 15.39 | 19.65 | 19.43 | 19.01 | 19.23 | 279,094 | 01:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Ragosa Mark |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [KNSA] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Interim CFO / | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Share Option | (1) | 5/22/2028 | Class A Common Shares | 18299 | $18.00 | D | |
Share Option | (2) | 9/19/2028 | Class A Common Shares | 20000 | $30.93 | D | |
Share Option | (3) | 3/3/2029 | Class A Common Shares | 12000 | $17.92 | D | |
Share Option | (4) | 9/16/2029 | Class A Common Shares | 12000 | $8.83 | D | |
Share Option | (5) | 3/12/2030 | Class A Common Shares | 20000 | $15.52 | D | |
Share Option | (6) | 9/9/2030 | Class A Common Shares | 22000 | $15.50 | D | |
Restricted Share Units | (7) | (7) | Class A Common Shares | 4404 | (8) | D |
Remarks: Exhibit 24 - Power of Attorney. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Ragosa Mark CLARENDON HOUSE 2 CHURCH STREET HAMILTON, D0 HM 11 | Interim CFO |
Signatures | ||
/s/ Mark Ragosa | 12/23/2020 | |
**Signature of Reporting Person | Date |
1 Year Kiniksa Pharmaceuticals Chart |
1 Month Kiniksa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions